Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine

BACKGROUND: Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expenditures, but most of the economic burden of migraine is socio...

Descripción completa

Detalles Bibliográficos
Autores principales: Siersbæk, Nikolaj, Kilsdal, Lærke, Jervelund, Christian, Antic, Sonja, Bendtsen, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316628/
https://www.ncbi.nlm.nih.gov/pubmed/37400756
http://dx.doi.org/10.1186/s12883-023-03302-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316628/
https://www.ncbi.nlm.nih.gov/pubmed/37400756
http://dx.doi.org/10.1186/s12883-023-03302-7

Ejemplares similares